CN113466469B - Biomarker, detection kit and detection system for autism detection - Google Patents
Biomarker, detection kit and detection system for autism detection Download PDFInfo
- Publication number
- CN113466469B CN113466469B CN202110765346.0A CN202110765346A CN113466469B CN 113466469 B CN113466469 B CN 113466469B CN 202110765346 A CN202110765346 A CN 202110765346A CN 113466469 B CN113466469 B CN 113466469B
- Authority
- CN
- China
- Prior art keywords
- autism
- bmaa
- severity
- serum
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000020706 Autistic disease Diseases 0.000 title claims abstract description 144
- 206010003805 Autism Diseases 0.000 title claims abstract description 140
- 238000001514 detection method Methods 0.000 title claims description 43
- 239000000090 biomarker Substances 0.000 title abstract description 12
- UJVHVMNGOZXSOZ-UHFFFAOYSA-N 2-amino-3-(methylamino)propanoic acid Chemical compound CNCC(N)C(O)=O UJVHVMNGOZXSOZ-UHFFFAOYSA-N 0.000 claims abstract description 76
- 210000002966 serum Anatomy 0.000 claims abstract description 39
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 16
- 238000002965 ELISA Methods 0.000 claims description 46
- 239000000243 solution Substances 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 20
- 239000008280 blood Substances 0.000 claims description 20
- 238000005406 washing Methods 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 9
- 238000011161 development Methods 0.000 claims description 8
- 241000283707 Capra Species 0.000 claims description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000008055 phosphate buffer solution Substances 0.000 claims description 3
- UJVHVMNGOZXSOZ-VKHMYHEASA-N L-BMAA Chemical compound CNC[C@H](N)C(O)=O UJVHVMNGOZXSOZ-VKHMYHEASA-N 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 17
- 238000011156 evaluation Methods 0.000 abstract description 8
- 239000012472 biological sample Substances 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 description 35
- 239000000523 sample Substances 0.000 description 23
- 238000000034 method Methods 0.000 description 16
- 229920001213 Polysorbate 20 Polymers 0.000 description 10
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 10
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000010009 beating Methods 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000012088 reference solution Substances 0.000 description 7
- 239000012086 standard solution Substances 0.000 description 7
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- 208000029560 autism spectrum disease Diseases 0.000 description 6
- 238000008157 ELISA kit Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000012089 stop solution Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 208000012202 Pervasive developmental disease Diseases 0.000 description 3
- 238000013211 curve analysis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 201000007197 atypical autism Diseases 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides a biomarker for detecting the severity of autism, namely the level of beta-methylamino-L-alanine (BMAA) in serum, so that the grading evaluation of the severity of autism does not depend on subjective experience judgment, and the diagnosis accuracy is greatly improved; the invention also provides a reagent combination for detecting the beta-methylamino-L-alanine (BMAA) level in serum, and the application thereof in preparing a kit for detecting autism; a system for testing biological samples of autistic patients to determine the severity of autism in the patients, by which the severity of autism can be rated in a hierarchical manner.
Description
Technical Field
The invention belongs to the field of biological medicines, and particularly relates to a biomarker, a detection kit and a detection system for detecting autism.
Background
Autism (autism), also known as autism or autistic disorder (autistic disorder), etc., is a representative disease of pervasive developmental disorder (pervasive developmental disorder, PDD). PDD is classified into 5 types by DSM-IV-TR: autistic disorder, retts syndrome, childhood disorganization disorder, asberg syndrome, and unspecified PDD. Among them, autistic disorder is more common with asberg syndrome. The prevalence of autism is reported differently, and is generally considered to be about 2-5/ten thousand of the child population, with a ratio of about 3-4:1 for men and women, and 3-4 times more for men and women than for women.
Autism is classified into true autism and pseudo-autism. True autism (organic autism) is a loss or severe loss of mental function in the brain due to a mutation in a gene. Their facial phase is quite different from that of ordinary people, but their congenital absence summarizes, generalizes, analyzes, judges and so on logic thinking ability, lifelong intelligence is low. Pseudo-autism (functional autism) refers to that the brain thinking area of the infant has no organic lesions and normal thinking ability, but the lack of intelligence is caused by unbalanced development of a certain ability in the acquired days. Essential differences exist between pseudo-autism and true autism. True autism is caused by gene mutation, the proportion of human true autism obtained by calculation is close to one fifteen parts per million, and it is estimated that the number of children with true autism per year in China is not more than 120, and the number of patients with true autism per year in the United states is lower than 36. True autism is a rare disease that should belong to. There is currently no effective rehabilitation solution. Pseudo-autism is due to imbalance in the development of several capacity elements that affect the ability of humans to learn. That is, if the ability is extremely weak or the ability is too strong, the child may lose part or all of the thinking ability, which results in life-long intellectual defect and shows the characteristics of true autism. The diagnosis and statistics of domestic hospitals show that the incidence rate of autism is 2-3 per mill, wherein the true autism accounts for less than 0.2 percent, and the false autism accounts for more than 99.8 percent.
In the 80 s of the 20 th century, research on autism entered an entirely new stage. The etiology hypothesis of the so-called "parental care method" has been abandoned, the etiology of autism has been explored from the biological field, and autism has been thoroughly separated from schizophrenia in terms of recognition of clinical symptoms and clinical diagnosis. The study of Kolvin shows that autism is not associated with adult psychotic disorders, particularly adult schizophrenia. The year of childhood autism was first identified as a pervasive developmental disorder by DSM-III published in 1980. Later, as the research on autism is in progress, it is gradually recognized that autism is a diffuse central nervous system development disorder disease caused by stimulation of various environmental factors under the action of certain genetic factors. Based on this knowledge, many studies have been conducted from molecular genetic to neuroimmunity, functional imaging, neuroanatomy, neurochemistry, and the like, and attempts have been made to find the causative agent of autism from these studies. There is no hypothesis that can explain the cause of autism radically and perfectly.
The current and more common method for diagnosing autism is to use the rating scale for autism in children. The table was compiled in 1980 by e.schopler, r.j. Reichler and b.r. Renner. The childhood autism rating scale is based on the child's performance, scoring fifteen aspects of child's interpersonal relationships, imitation (words and actions), emotional response, physical exertion, relationship to inanimate objects, adaptation to environmental changes, visual response, auditory response, near sensory response, anxiety response, verbal communication, non-verbal communication, activity level, mental function, and general impression. The scoring criteria are as follows: the total score is lower than 30: no autism; 30-60 minutes: has autism; wherein the content of the components is 30-37: is a mild to moderate autism; 37-60 minutes: severe autism.
The method mainly depends on subjective experience judgment, and can influence the accuracy of diagnosis and the grading evaluation of the severity of the autism.
Disclosure of Invention
To address the deficiencies of the prior art, it is an object of the present invention to provide a biomarker for autism detection characterized by comprising beta-methylamino-L-alanine (BMAA) levels in serum.
It is an object of the present invention to provide the use of said biomarker for autism detection in a system for detecting a biological sample of an autism patient.
It is an object of the present invention to provide the use of a combination of reagents for detecting beta-methylamino-L-alanine (BMAA) levels in serum for the preparation of a kit for detecting autism.
Preferably, the combination of reagents for detecting beta-methylamino-L-alanine (BMAA) levels in serum comprises an ELISA detection reagent;
the ELISA detection reagent comprises phosphate buffer solution of goat anti-rabbit antibody; freeze-drying BMAA calibrator/standard;
rabbit anti-BMAA antibody solution; HRP-labeled BMAA solution; a washing liquid; TMB color development liquid; and (5) stopping liquid.
Preferably, the use of the kit for detecting autism comprises the steps of:
obtaining a blood sample from a subject;
centrifuging the blood sample to obtain serum;
the serum is subjected to ELISA detection, and the severity of autism is determined according to the level of beta-methylamino-L-alanine (BMAA) contained in the serum of the subject.
Preferably, the step of centrifuging the blood sample to obtain serum comprises the steps of: collecting 3ml of venous blood from a tested individual, and centrifuging at 3000rpm for 5 minutes to obtain a supernatant serving as a serum sample;
the ELISA detection of serum and the determination of the severity of autism according to the level of beta-methylamino-L-alanine (BMAA) contained in the serum of the tested individual according to the result of ELISA detection comprise the following steps:
step one: PBS containing 1 mug/ml goat anti-rabbit antibody is added into ELISA reaction plate, and the ELISA reaction plate is incubated for 16 hours at 4 ℃ in a sealing way; drying the reaction plate by beating, washing the plate hole with PBS containing 0.2% Tween-20, and drying the reaction plate by beating to obtain a coated ELISA plate;
step two: the lyophilized BMAA calibrator/standard was dissolved in purified water to give diluted BMAA calibrator/standard concentrations of 0ppb, 5ppb, 25ppb, 100ppb, 250ppb, 500ppb, respectively.
Step three: the following solutions were added to the coated ELISA plate wells: 100. Mu.l of BMAA reference/standard solution or 100. Mu.l of serum sample solution, 50. Mu.l of BMAA-HRP binding solution, 50. Mu.l of rabbit anti-BMAA antibody solution. At least 2 replicate wells were made per BMAA reference/standard solution or sample;
step four: after mixing for 30 seconds, incubating for 90 minutes at room temperature in a dark place;
step five: the contents of the wells were decanted and each well was washed with at least 250 μl of 0.2% tween-20 in PBS, the plates were dried and repeated four times. After washing the plate, 150 μl of TMB developing solution is added into each reaction plate hole, the mixture is uniformly mixed for 30 seconds, the mixture is placed at room temperature and kept away from light for 30 minutes, and then 100 μl of stop solution is added into each hole to stop the reaction;
step six: within 15 minutes after terminating the reaction, placing the reaction plate in an enzyme labeling instrument, and reading an OD450 value;
step seven: drawing a standard curve, and calculating the concentration of the BMAA in the sample according to the standard curve;
step eight: a graded assessment of autism severity was made based on the concentration of BMAA in the samples.
It is an object of the present invention to provide a kit for diagnosing autism comprising reagents suitable for detecting the biomarker according to claim 1.
Preferably, the reagent suitable for detecting the biomarker of claim 1 comprises an ELISA detection reagent;
the ELISA detection reagent comprises phosphate buffer solution of goat anti-rabbit antibody; freeze-drying BMAA calibrator/standard;
rabbit anti-BMAA antibody solution; HRP-labeled BMAA solution; a washing liquid; TMB color development liquid; and (5) stopping liquid.
Preferably, the method for using the kit for diagnosing autism comprises the following steps:
obtaining a blood sample from a subject;
centrifuging the blood sample to obtain serum;
the serum is subjected to ELISA detection, and the severity of autism of the patient is determined according to the beta-methylamino-L-alanine (BMAA) level contained in the serum of the patient as a result of ELISA detection.
Preferably, the step of centrifuging the blood sample to obtain serum comprises the steps of: venous blood (3 ml) was collected and then centrifuged at 3000rpm for 5 minutes to obtain a serum sample.
The ELISA detection of the serum and the determination of the severity of the autism of the patient according to the beta-methylamino-L-alanine (BMAA) level in the serum of the patient according to the ELISA detection result comprise the following steps:
step one: PBS containing 1 mug/ml goat anti-rabbit antibody is added into ELISA reaction plate, and the ELISA reaction plate is incubated for 16 hours at 4 ℃ in a sealing way; drying the reaction plate by beating, washing the plate hole with PBS containing 0.2% Tween-20, and drying the reaction plate by beating to obtain a coated ELISA plate;
step two: dissolving the freeze-dried BMAA calibrator/standard with purified water, wherein the concentration of the diluted BMAA calibrator/standard is respectively 0ppb, 5ppb, 25ppb, 100ppb, 250ppb and 500ppb;
step three: the following solutions were added to the coated ELISA plate wells: 100. Mu.l BMAA reference/standard solution or 100. Mu.l sample solution, 50. Mu.l BMAA-HRP binding solution, 50. Mu.l BMAA antibody solution. At least 2 replicate wells were made per BMAA reference/standard solution or sample;
step four: after mixing for 30 seconds, incubating for 90 minutes at room temperature in a dark place;
step five: the contents of the wells were decanted and each well was washed with at least 250 μl of 0.2% tween-20 in PBS, the plates were dried and repeated four times. After washing the plate, 150 μl of TMB developing solution is added into each reaction plate hole, the mixture is uniformly mixed for 30 seconds, the mixture is placed at room temperature and kept away from light for 30 minutes, and then 100 μl of stop solution is added into each hole to stop the reaction;
step six: within 15 minutes after terminating the reaction, placing the reaction plate in an enzyme labeling instrument, and reading an OD450 value;
step seven: drawing a standard curve, and calculating the concentration of the BMAA in the sample according to the standard curve;
step eight: a graded assessment of autism severity was made based on the concentration of BMAA in the samples.
It is an object of the present invention to provide a system for testing a biological sample of an autistic patient to determine the severity of autism in the patient, comprising:
a blood processing device for centrifuging a sample to be measured taken from an individual to be measured to obtain serum;
the ELISA detection device is connected with the blood treatment device and is used for detecting an ELISA value of serum treated by the ELISA detection reagent; and
and the analysis device is connected with the ELISA detection device, performs concentration analysis on the biomarker contained in the ELISA detection device based on the ELISA value, and judges the severity of the autism of the tested individual of the sample to be tested according to the analysis result.
Preferably, the blood processing apparatus comprises the steps of: venous blood (3 ml) was collected and then centrifuged at 3000rpm for 5 minutes to obtain a serum sample.
The ELISA detection device and the analysis device comprise the following operation steps:
step one: PBS containing 1 mug/ml goat anti-rabbit antibody is added into ELISA reaction plate, and the ELISA reaction plate is incubated for 16 hours at 4 ℃ in a sealing way; drying the reaction plate by beating, washing the plate hole with PBS containing 0.2% Tween-20, and drying the reaction plate by beating to obtain a coated ELISA plate;
step two: the lyophilized BMAA calibrator/standard was dissolved in purified water and the concentrations of the diluted BMAA calibrator/standard were 0, 5, 25, 100, 250, 500 (ppb), respectively.
Step three: the following solutions were added to the coated ELISA plate wells: 100. Mu.l BMAA reference/standard solution or 100. Mu.l sample solution, 50. Mu.l BMAA-HRP binding solution, 50. Mu.l BMAA antibody solution. At least 2 replicate wells were made per BMAA reference/standard solution or sample.
Step four: after mixing for 30 seconds, incubation was carried out at room temperature for 90 minutes in the dark.
Step five: the contents of the wells were decanted and each well was washed with at least 250 μl of 0.2% tween-20 in PBS, the plates were dried and repeated four times. After washing the plate, 150 μl of TMB developing solution is added into each reaction plate hole, the mixture is uniformly mixed for 30 seconds, the mixture is placed at room temperature and kept away from light for 30 minutes, and then 100 μl of stop solution is added into each hole to stop the reaction;
step six: within 15 minutes after termination of the reaction, the reaction plate was placed in a microplate reader and the OD450 values were read.
Step seven: and drawing a standard curve, and calculating the concentration of the BMAA in the sample according to the standard curve.
Step eight: a graded assessment of autism severity was made based on the concentration of BMAA in the samples.
In this patent, the term "biomarker" is to be understood in a broad sense and includes any detectable biological indicator capable of reflecting an abnormal condition, and may include genetic markers, species markers (species markers/genus markers) and functional markers (KO/OG markers), which have a very broad range of uses, for disease diagnosis, for judging disease stage or for evaluating the safety and effectiveness of a new drug or new therapy in a target population.
In addition, in the present invention, the agent for detecting BMAA or measuring BMAA level is an antibody, and the corresponding BMAA or measuring BMAA level can be detected by using an immunological method based on an antigen-antibody reaction. As the analytical method used for this, western blotting, enzyme-linked immunosorbent assay (ELlSA, enzyme linked immunosorbent asay), radioimmunoassay (RIA: radio immunoassay), radioimmunoassay (radioimmunodiffusion), european (Ouchterlony) immunodiffusion, rocket (socket) immunoelectrophoresis, tissue immunostaining, immunoprecipitation assay (Immunoprecipitation assay), complement fixation assay (Complement Fixation Assay), fluorescence activated cell sorter (FACS, fluorescence activated cell sorter), protein chip (protein chip) and the like are mentioned, and the present invention is not limited to the above-mentioned method.
The invention has the following beneficial effects:
in the course of conducting studies on the correlation between autism and intestinal microorganisms, the present inventors found that there is a significant correlation between procaryotic species of the intestinal microorganisms and the occurrence of autism, which indicates that procaryotic species of the intestinal microorganisms have a close relationship with the occurrence of autism. While beta-methylamino-L-alanine (BMAA) is a neurotoxin secreted by the prokaryote, the present invention found that the concentration of beta-methylamino-L-alanine (BMAA) has a significant correlation with the severity of autism, and the higher the BMAA concentration, the more severe the autism. Indicating that BMAA may be a significant cause of autism. The invention takes the BMAA content in serum as a detection marker for classifying the severity of the autism, and determines the severity of the autism by detecting the concentration of the BMAA, thereby changing the method for diagnosing the autism by means of the autism rating scale and determining the severity of the autism, overcoming the defect that the diagnosis of the severity classification of the autism is greatly dependent on subjective experience judgment, and greatly improving the diagnosis accuracy.
The kit provided by the invention only needs about 3 hours for detection, and only needs to perform venous blood sampling on patients suffering from autism. Compared with the existing autism detection technology, the ELISA detection kit has the characteristics of objectivity, simplicity, convenience, rapidness and the like, reduces the participation time of autism patients, and also greatly reduces the working difficulty of medical staff.
Furthermore, compared with the method for diagnosing autism and determining the severity of autism by means of the autism rating scale, the method has the advantages that the concentration sensitivity of BMAA is high, even if the concentration of BMAA slightly changes, the method can be used for detecting the BMAA, and therefore, the method can be widely applied in future, such as clinical evaluation of curative effects of autism treatment, dynamic monitoring of illness states of autism patients and the like.
Drawings
FIG. 1 is a graph of ROC curve analysis of the detection and grading of autism severity by ELISA kit of the invention.
Detailed Description
The invention will now be described in further detail with reference to the drawings and examples. The following examples are only illustrative of the present invention and are not intended to limit the scope of the invention. The experimental procedure, without specific conditions noted in the examples, is generally followed by conventional conditions, such as Sambrook et al, molecular cloning: conditions described in the laboratory Manual (New York: cold Spring HarborLaboratory Press, 1989) or as recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
In order to evaluate whether the concentration of BMAA in serum can be used as an evaluation factor of the severity of autism, the invention detects the concentration of BMAA in serum of autism patients by collecting blood samples of the autism patients and evaluates the grading condition of the severity of autism of the patients according to the concentration through ELISA experiments, and then compares the grading condition with the diagnosis result of a doctor through a childhood autism rating scale to find that the consistency of the results reaches 90%, which indicates that the ELISA kit provided by the invention can replace the childhood autism rating scale to be used for grading evaluation of the severity of autism.
Example 1
In this example, blood samples from autistic patients were analyzed using ELISA detection and then statistically analyzed to determine whether the concentration of BMAA could be used as a biomarker for the graded assessment of autism and severity of illness. The method comprises the following specific steps:
1. sample source
Sample sources and inclusion criteria were as follows:
patients diagnosed with autism. Exclusion criteria: (1) suffering from other mental disorders (such as schizophrenia) and other neurological disorders; (2) suffering from a genetic metabolic disease; (3) a history of major somatic diseases with severe neurological disease and craniocerebral injury Shi Dengchong;
the study was divided into two phases: the comparison study of the consistency of the diagnosis results of the invention and the autism rating scale is carried out in the first period, and the comparison study of the sensitivity of the diagnosis method of the invention and the autism rating scale is carried out in the second period.
10 cases of autism infants, 9 men and 1 woman are collected in the first-period study; age 3-7 years old;
9 cases of infants are collected in the second-stage study, wherein 6 cases of infants suffering from autism and 3 cases of infants suffering from development retardation, 6 cases of infants suffering from autism and 0 cases of women; aged 3-7 years. 3 cases of infants suffering from development retardation, 1 case of men and 2 cases of women; aged 3-7 years.
Blood collection and acquisition of supernatant:
venous blood was collected in a disposable blood collection tube at about 3ml, and then centrifuged at 3000rpm for 5 minutes with a centrifuge, and the supernatant was collected as a serum sample.
ELISA detection:
and (3) coating a reaction plate: PBS containing 1 mug/ml goat anti-rabbit antibody is added into ELISA reaction plate, and the ELISA reaction plate is incubated for 16 hours at 4 ℃ in a sealing way; drying the reaction plate by beating, washing the plate hole with PBS containing 0.2% Tween-20, and drying the reaction plate by beating to obtain a coated ELISA plate;
reference/standard solution was added: 100 μl of diluted BMAA calibrator/standard is added into the coated ELISA plate well in sequence, and the concentrations are 0ppb, 5ppb, 25ppb, 100ppb, 250ppb and 500ppb respectively. At least two parallel wells were made for each concentration.
Serum samples were added: 100 μl of each serum sample was added sequentially to the wells of the other coated ELISA plates.
Adding a binding solution: mu.l BMAA-HRP conjugate was added to each well.
Adding an antibody solution: mu.l of BMAA antibody solution was added to each well.
Incubation: after mixing for 30 seconds, incubation was carried out at room temperature for 90 minutes in the dark.
Washing the plate: the contents of the wells were decanted and each well was washed with at least 250 μl of 0.2% tween-20 in PBS, the plates were dried and repeated four times.
Color development and reaction termination: after washing the plate, 150 μl of TMB developing solution is added into each reaction plate hole, the mixture is uniformly mixed for 30 seconds, the mixture is placed at room temperature and kept away from light for 30 minutes, and then 100 μl of stop solution is added into each hole to stop the reaction;
and (3) detection: within 15 minutes after termination of the reaction, the reaction plate was placed in a microplate reader and the OD450 values were read.
Calculate BMAA concentration of sample: and drawing a standard curve of absorbance at 450nm of the standard substance and BMAA concentration, and calculating the BMAA concentration of the sample according to the standard curve.
Grading evaluation of autism severity: the severity of autism in the serum subjects was determined based on the BMAA concentration of the samples.
The kit detects BMAA concentration and autism severity evaluation criteria: BMAA concentration less than or equal to 101ppb, and autism severity from mild to moderate; BMAA concentrations >101ppb, with autism severity severe.
The preparation method of the reagent involved in each step comprises the following steps:
PBS: weighing potassium dihydrogen phosphate (KH) 2 PO 4 ) 0.2g of disodium hydrogen phosphate (Na 2 HPO 4 ·12H 2 0) 2.9g of sodium chloride (NaCl) 8.0g, potassium chloride (KCI) 0.2g, and water to 1000mL.
PBS containing 0.2% Tween-20: weighing potassium dihydrogen phosphate (KH) 2 PO 4 ) 0.2g of disodium hydrogen phosphate(Na 2 HPO 4 ·12H 2 0) 2.9g of sodium chloride (NaCl) 8.0g, potassium chloride (KCI) 0.2g, tween-20 2mL, and water to 1000mL.
Statistical analysis
4.1. The invention analyzes consistency of the diagnosis result of the autism rating scale
10 patient samples were diagnosed using the kit of the present invention and the autism rating scale, the results are shown in Table 1
TABLE 1 diagnosis of 10 patient samples using ELISA kits of the invention and autism rating scale, respectively
The two methods for evaluating the severity of the autism are inconsistent in only 1 case, and the severity of the autism detected by the ELISA kit disclosed by the invention is consistent with the diagnosis result of the autism rating scale commonly adopted at present by 90%.
4.2. Sensitivity analysis of the invention and autism rating scale diagnosis
Diagnosis of 9 donor samples using the kit of the present invention and the autism rating scale are shown in Table 2
TABLE 2 diagnosis of 9 blood samples using ELISA kit and autism rating scale according to the present invention, respectively
For the detection of patients with autism, only 1 case of the two methods for evaluating the severity of autism has inconsistent; in addition, although the doctor considers that the diagnosis of the autism rating scale adopted in 3 cases is not autism but is considered to be slow, the severity of the autism can be judged by the detection of the kit of the invention. It can be seen that the sensitivity of the kit of the invention is stronger than the currently commonly used autism rating scale. At present, 3 children suffering from hypoevolutism are also subjected to rehabilitation training of autism, and the disease conditions and the autism are quite similar. But if assessed as developing slowly, may result in the unappreciation of the parent, thereby delaying intervention and treatment of the condition. From this point of view, it is very important that the present invention has higher sensitivity.
4.3. The invention replaces the feasibility and the necessity of the autism rating scale for diagnosing the severity of the autism
The statistical analysis of the diagnosis results of the severity of 16 autism patients by using the kit and the autism rating scale shows that the detected toxin concentration of the kit has obvious correlation with the autism rating scale evaluation result, the correlation coefficient is 1.00, and the P value is 0.011. The results are shown in Table 3.
ROC curve analysis of the grading result of the severity of the autism of the kit shows that A mu C is 0.857, P value is 0.017, and the kit has statistical significance. The optimal critical value is 101.1617, the corresponding specificity is 0.889, and the sensitivity is 0.857 (see figure 1), which indicates that the kit has higher sensitivity and specificity when applied to the detection of the severity of autism.
The experimental result shows that the BMAA concentration in the serum of the patient has obvious correlation with the severity of the autism, so that the detection of the BMAA concentration in the serum of the patient by using the kit disclosed by the invention is feasible to determine the severity of the autism, and the ROC curve analysis result also shows that the kit disclosed by the invention has higher sensitivity and specificity when applied to the detection of the severity of the autism.
In addition, the kit adopts an ELISA method to detect the BMAA concentration in the serum of a patient, and the sensitivity of ELISA can reach ng level, so that the change of the BMAA concentration in the serum of the patient can be detected very sensitively, which is very beneficial to the treatment effect of the patient with autism and the judgment of the change condition of the patient with autism, and the kit has strong feasibility and necessity for diagnosing the severity of autism by using the autism rating scale instead of the autism rating scale.
TABLE 3 correlation of detected toxin concentrations with autism rating scale for the kit of the invention
Correlation coefficient
* At a confidence level (double test) of 0.05, the correlation was significant.
Claims (3)
1. Use of a combination of reagents for detecting β -methylamino-L-alanine BMAA levels in serum in the manufacture of a kit for detecting the severity of autism.
2. The use of claim 1, wherein the combination of reagents for detecting β -methylamino-L-alanine BMAA levels in serum comprises an ELISA detection reagent; the ELISA detection reagent comprises phosphate buffer solution of goat anti-rabbit antibody; freeze-drying BMAA calibrator/standard; rabbit anti-BMAA antibody solution; HRP-labeled BMAA solution; a washing liquid; TMB color development liquid; and (5) stopping liquid.
3. The use according to claim 2, wherein the use of the kit for detecting the severity of autism comprises the steps of:
obtaining a blood sample from a subject;
centrifuging the blood sample to obtain serum;
the serum is subjected to ELISA detection, and the severity of autism is determined according to the level of beta-methylamino-L-alanine BMAA contained in the serum of the tested individual as a result of ELISA detection.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310445987.7A CN116593706A (en) | 2021-07-07 | 2021-07-07 | Application of beta-methylamino-L-alanine serving as target spot in preparation of kit for detecting autism |
| CN202110765346.0A CN113466469B (en) | 2021-07-07 | 2021-07-07 | Biomarker, detection kit and detection system for autism detection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110765346.0A CN113466469B (en) | 2021-07-07 | 2021-07-07 | Biomarker, detection kit and detection system for autism detection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310445987.7A Division CN116593706A (en) | 2021-07-07 | 2021-07-07 | Application of beta-methylamino-L-alanine serving as target spot in preparation of kit for detecting autism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113466469A CN113466469A (en) | 2021-10-01 |
| CN113466469B true CN113466469B (en) | 2024-01-16 |
Family
ID=77878756
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110765346.0A Active CN113466469B (en) | 2021-07-07 | 2021-07-07 | Biomarker, detection kit and detection system for autism detection |
| CN202310445987.7A Withdrawn CN116593706A (en) | 2021-07-07 | 2021-07-07 | Application of beta-methylamino-L-alanine serving as target spot in preparation of kit for detecting autism |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310445987.7A Withdrawn CN116593706A (en) | 2021-07-07 | 2021-07-07 | Application of beta-methylamino-L-alanine serving as target spot in preparation of kit for detecting autism |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN113466469B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1860369A (en) * | 2003-08-12 | 2006-11-08 | 种族医学学会 | Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders |
| CN103308639A (en) * | 2013-05-17 | 2013-09-18 | 南京大学 | Detection method of content of blue algae toxin beta-methylamino-L-alanine in aquatic products |
| CN107058560A (en) * | 2017-05-04 | 2017-08-18 | 深圳市英马诺生物科技有限公司 | Self-closing disease biomarker and its detection kit, application |
| CN107167610A (en) * | 2017-05-04 | 2017-09-15 | 深圳市英马诺生物科技有限公司 | Self-closing disease biomarker and its detection kit |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102359013B1 (en) * | 2017-03-21 | 2022-02-04 | 콰드런트 바이오사이언시즈 인코포레이티드 | Analysis of Autism Spectrum Disorders |
| EP4069868A4 (en) * | 2019-12-02 | 2024-04-17 | The Institute For Ethnomedicine DBA Brain Chemistry Labs | Methods of detection and analysis of nucleic acid in neural-derived exosomes |
-
2021
- 2021-07-07 CN CN202110765346.0A patent/CN113466469B/en active Active
- 2021-07-07 CN CN202310445987.7A patent/CN116593706A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1860369A (en) * | 2003-08-12 | 2006-11-08 | 种族医学学会 | Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders |
| CN103308639A (en) * | 2013-05-17 | 2013-09-18 | 南京大学 | Detection method of content of blue algae toxin beta-methylamino-L-alanine in aquatic products |
| CN107058560A (en) * | 2017-05-04 | 2017-08-18 | 深圳市英马诺生物科技有限公司 | Self-closing disease biomarker and its detection kit, application |
| CN107167610A (en) * | 2017-05-04 | 2017-09-15 | 深圳市英马诺生物科技有限公司 | Self-closing disease biomarker and its detection kit |
Non-Patent Citations (2)
| Title |
|---|
| Perinatal Exposure to the Cyanotoxin β-N-Méthylamino-L-Alanine (BMAA) Results in Long-Lasting;Anthony Laugeray等;《Neurotox Res》;20170906;第33卷;第87-112页 * |
| 阿尔茨海默病与肠道菌群的关系及菌群调节对其防治的展望;周珂新等;《中国药理学与毒理学杂志》;20161115(第11期);第1198-1205页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116593706A (en) | 2023-08-15 |
| CN113466469A (en) | 2021-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7192724B2 (en) | Method for differentiating irritable bowel syndrome from inflammatory bowel disease (IBD) and for monitoring persons with IBD using total endogenous lactoferrin as a marker | |
| García et al. | The use of IgE immunoblotting as a diagnostic tool in Anisakis simplex allergy | |
| EP1554580A2 (en) | Inflammatory bowel disease and irritable bowel syndrome ibd-first chek diagnostic panel | |
| CN107167610B (en) | autism biomarker and detection kit thereof | |
| CN110726846B (en) | Application of HBP protein as diagnostic marker of Kawasaki disease | |
| US20100227333A1 (en) | Method of detecting infection with urogenital mycoplasmas in humans and a kit for diagnosing same | |
| CN113192552A (en) | Active tuberculosis marker, kit, detection method and model construction method | |
| CN106153893B (en) | The enzyme-linked immunologic detecting kit of saliva anti-mitochondrial antibody M2 types | |
| CN113466469B (en) | Biomarker, detection kit and detection system for autism detection | |
| CN108982868B (en) | Application of nucleosomal protein SP110 and kit containing same in preparation of alcoholic cardiomyopathy early diagnosis reagent | |
| CN116559460A (en) | Biomarker, detection kit and detection system for autism detection | |
| CN115932278A (en) | Detection method of anti-gamma interferon autoantibody | |
| CN110117648B (en) | Circadian rhythm sleep disorder biomarkers | |
| CN111415745A (en) | Calculation method for prompting Alzheimer disease risk of elderly men by androgen | |
| CN111856035A (en) | Application of TNC protein detection reagent and kit | |
| CN112881690B (en) | Respiratory syncytial virus related protein marker TPI1 and detection kit | |
| Ong et al. | The LaBrosse VMA spot test revisited | |
| CN113984920B (en) | Application of substance for detecting beta-aminoisobutyric acid, tryptophan and taurine in preparing auxiliary diagnosis kit for cerebral palsy | |
| CN106908600B (en) | One kind being used for the kit of detection system lupus erythematosus (SLE) | |
| CN113834939A (en) | Reagent and kit for detecting Kawasaki disease and evaluating curative effect and application | |
| CN117741154A (en) | Biomarker combination for cognitive impairment detection and application | |
| CN117805391A (en) | Biomarker for detecting early mild cognitive impairment and/or Alzheimer's disease and application thereof | |
| CN111751547A (en) | Serum polypeptide marker F for tic disorder and detection method thereof | |
| CN116087521A (en) | Three serum marker protein combined detection ELISA kit for early screening and diagnosis of brain glioma | |
| CN114966005A (en) | Grouping method for improving accuracy of prediction of severe dengue infection individuals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20211001 Assignee: Beijing Changshunning Biotechnology Co.,Ltd. Assignor: Beijing Changyou Biotechnology Co.,Ltd. Contract record no.: X2024980006639 Denomination of invention: Biomarkers, testing kits, and testing systems for autism detection Granted publication date: 20240116 License type: Exclusive License Record date: 20240603 |
|
| EE01 | Entry into force of recordation of patent licensing contract |